Display:
Providers:
Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Core Illumina products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. GRAIL is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Customers use its platforms to perform whole genome, de novo, exome and ribonucleic acid (RNA) sequencing, and targeted resequencing of specific gene regions and genes. The Company's BeadArray technology produces arrays that can perform many assays simultaneously. Customers use its array-based genotyping consumables for a range of analyses, including diverse species, disease-related mutations, and genetic characteristics associated with cancer.
|
|
|
|
|
Yesterday's News, May 16, 2022 | ||
---|---|---|
May 13, 2022 | ||
May 12, 2022 | ||
May 11, 2022 | ||
May 10, 2022 | ||
May 09, 2022 | ||
May 06, 2022 | ||
May 05, 2022 | ||
May 04, 2022 | ||
May 03, 2022 | ||
May 02, 2022 | ||
April 29, 2022 | ||
April 28, 2022 | ||
April 27, 2022 | ||
April 26, 2022 | ||
April 25, 2022 | ||
April 22, 2022 | ||
April 20, 2022 | ||
April 19, 2022 | ||
Next > |
Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.
Copyright © 2022. All rights reserved.